SIMILAR PATTERN OF AMINO ACIDS MAPPED TO '4oav'

List of Similar Pattern of Amino Acids

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click on the DrReposER ID to view details on interfaces and similar patterns of amino acids)
(Click on the view link on the last column to view superposed patterns of amino acids)

Filter list by:

	DrReposER ID / Desc.	Hit PDBID	Hit Macromolecule	Res. Matches	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1DMA_B_NCAB700_0 (EXOTOXIN A)	4oav	PROTEIN (RNASE L) (Homo sapiens)	4 / 6	HIS B 180 TYR B 135 ALA B 133 GLU B 131	None None None A C 3 ( 2.7A)	1.01A	1dmaB-4oavB: undetectable	1dmaB-4oavB: 14.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1EQG_A_IBPA701_1 (PROSTAGLANDIN H2 SYNTHASE-1)	4oav	PROTEIN (RNASE L) (Homo sapiens)	5 / 9	VAL B 418 VAL B 432 LEU B 408 ILE B 379 ALA B 390	None None None ACP B 801 (-4.0A) ACP B 801 (-3.2A)	1.09A	1eqgA-4oavB: undetectable	1eqgA-4oavB: 22.55
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1EQG_B_IBPB1701_1 (PROSTAGLANDIN H2 SYNTHASE-1)	4oav	PROTEIN (RNASE L) (Homo sapiens)	5 / 11	VAL B 418 VAL B 432 LEU B 408 ILE B 379 ALA B 390	None None None ACP B 801 (-4.0A) ACP B 801 (-3.2A)	1.08A	1eqgB-4oavB: undetectable	1eqgB-4oavB: 22.55
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1MRQ_A_STRA501_1 (ALDO-KETO REDUCTASE FAMILY 1 MEMBER C1)	4oav	PROTEIN (RNASE L) (Homo sapiens)	5 / 11	LEU B 707 GLU B 613 ILE B 614 LEU B 596 LEU B 663	None	1.35A	1mrqA-4oavB: undetectable	1mrqA-4oavB: 19.51
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1RS6_B_MTLB871_0 (NITRIC-OXIDE SYNTHASE, BRAIN)	4oav	PROTEIN (RNASE L) (Homo sapiens)	4 / 8	ARG B 597 GLN B 693 PHE B 692 ASP B 687	None	1.31A	1rs6B-4oavB: undetectable	1rs6B-4oavB: 20.79
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1UWH_A_BAXA1723_1 (B-RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE)	4oav	PROTEIN (RNASE L) (Homo sapiens)	5 / 12	ALA B 390 LEU B 408 CYH B 437 LEU B 475 HIS B 483	ACP B 801 (-3.2A) None ACP B 801 (-4.5A) None None	0.66A	1uwhA-4oavB: 17.1	1uwhA-4oavB: 18.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1UWH_B_BAXB1723_1 (B-RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE)	4oav	PROTEIN (RNASE L) (Homo sapiens)	6 / 12	ALA B 390 LYS B 392 LEU B 408 CYH B 437 LEU B 475 HIS B 483	ACP B 801 (-3.2A) ACP B 801 (-2.8A) None ACP B 801 (-4.5A) None None	0.79A	1uwhB-4oavB: 17.1	1uwhB-4oavB: 18.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XZX_X_T3X500_2 (THYROID HORMONE RECEPTOR BETA-1)	4oav	PROTEIN (RNASE L) (Homo sapiens)	3 / 3	PHE B 716 ARG B 597 ASN B 598	None	0.85A	1xzxX-4oavB: undetectable	1xzxX-4oavB: 16.14
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1ZZQ_A_MTLA870_0 (NITRIC-OXIDE SYNTHASE, BRAIN)	4oav	PROTEIN (RNASE L) (Homo sapiens)	4 / 8	ARG B 597 GLN B 693 PHE B 692 ASP B 687	None	1.29A	1zzqA-4oavB: undetectable	1zzqA-4oavB: 20.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1ZZQ_B_MTLB871_0 (NITRIC-OXIDE SYNTHASE, BRAIN)	4oav	PROTEIN (RNASE L) (Homo sapiens)	4 / 8	ARG B 597 GLN B 693 PHE B 692 ASP B 687	None	1.27A	1zzqB-4oavB: undetectable	1zzqB-4oavB: 20.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2BXQ_A_IMNA2001_1 (SERUM ALBUMIN)	4oav	PROTEIN (RNASE L) (Homo sapiens)	5 / 10	ALA B 128 PHE B 129 ALA B 133 LEU B 187 LEU B 108	None	1.06A	2bxqA-4oavB: 2.6	2bxqA-4oavB: 22.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2C49_B_ADNB1301_1 (SUGAR KINASE MJ0406)	4oav	PROTEIN (RNASE L) (Homo sapiens)	5 / 7	ALA B 169 GLY B 168 GLY B 167 ASN B 200 PHE B 126	A C 3 ( 4.6A) None A C 3 ( 4.4A) None A C 3 ( 3.6A)	1.16A	2c49B-4oavB: undetectable	2c49B-4oavB: 18.30
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2EUF_B_LQQB401_1 (CELL DIVISION PROTEIN KINASE 6)	4oav	PROTEIN (RNASE L) (Homo sapiens)	7 / 12	ILE B 371 LYS B 392 VAL B 418 ASN B 490 LEU B 492 ALA B 502 ASP B 503	ACP B 801 (-4.2A) ACP B 801 (-2.8A) None MG B 802 ( 2.5A) ACP B 801 (-4.5A) None MG B 803 (-1.8A)	0.81A	2eufB-4oavB: 19.6	2eufB-4oavB: 18.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2PNJ_A_CHDA501_0 (FERROCHELATASE, MITOCHONDRIAL)	4oav	PROTEIN (RNASE L) (Homo sapiens)	5 / 12	LEU B 527 LEU B 524 LEU B 521 ILE B 491 LEU B 477	None	1.09A	2pnjA-4oavB: undetectable	2pnjA-4oavB: 19.80
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y7H_B_SAMB530_0 (TYPE I RESTRICTION ENZYME ECOKI M PROTEIN)	4oav	PROTEIN (RNASE L) (Homo sapiens)	5 / 12	ILE B 371 ALA B 502 THR B 440 LEU B 475 PHE B 504	ACP B 801 (-4.2A) None ACP B 801 (-4.1A) None None	1.08A	2y7hB-4oavB: undetectable	2y7hB-4oavB: 21.92
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y7H_C_SAMC530_0 (TYPE I RESTRICTION ENZYME ECOKI M PROTEIN)	4oav	PROTEIN (RNASE L) (Homo sapiens)	5 / 12	ILE B 371 ALA B 502 THR B 440 LEU B 475 PHE B 504	ACP B 801 (-4.2A) None ACP B 801 (-4.1A) None None	1.07A	2y7hC-4oavB: undetectable	2y7hC-4oavB: 21.92
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3IK3_A_0LIA1_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	4oav	PROTEIN (RNASE L) (Homo sapiens)	6 / 12	ALA B 390 LEU B 417 VAL B 418 HIS B 483 LEU B 492 ALA B 502	ACP B 801 (-3.2A) None None None ACP B 801 (-4.5A) None	0.74A	3ik3A-4oavB: 16.8	3ik3A-4oavB: 17.11
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3IK3_B_0LIB2_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	4oav	PROTEIN (RNASE L) (Homo sapiens)	5 / 12	ALA B 390 LEU B 417 HIS B 483 LEU B 492 ALA B 502	ACP B 801 (-3.2A) None None ACP B 801 (-4.5A) None	0.57A	3ik3B-4oavB: 16.6	3ik3B-4oavB: 17.11
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3IK3_B_0LIB2_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	4oav	PROTEIN (RNASE L) (Homo sapiens)	5 / 12	LEU B 417 VAL B 418 HIS B 483 LEU B 492 ALA B 502	None None None ACP B 801 (-4.5A) None	0.70A	3ik3B-4oavB: 16.6	3ik3B-4oavB: 17.11
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3WIP_G_ACTG305_0 (ACETYLCHOLINE-BINDIN G PROTEIN)	4oav	PROTEIN (RNASE L) (Homo sapiens)	3 / 3	ASP B 485 ARG B 400 LYS B 506	MG B 803 (-4.7A) ACP B 801 (-3.1A) ACP B 801 ( 4.8A)	0.95A	3wipG-4oavB: undetectable	3wipG-4oavB: 15.87
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4AGD_A_B49A2000_1 (VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2)	4oav	PROTEIN (RNASE L) (Homo sapiens)	5 / 11	ALA B 390 VAL B 418 VAL B 434 CYH B 437 LEU B 492	ACP B 801 (-3.2A) None ACP B 801 (-4.8A) ACP B 801 (-4.5A) ACP B 801 (-4.5A)	0.55A	4agdA-4oavB: 17.0	4agdA-4oavB: 19.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4DX7_A_DM2A1105_1 (ACRIFLAVINE RESISTANCE PROTEIN B)	4oav	PROTEIN (RNASE L) (Homo sapiens)	5 / 11	MET B 130 PHE B 126 GLY B 202 ARG B 154 GLU B 162	None A C 3 ( 3.6A) None None None	1.48A	4dx7A-4oavB: 0.1	4dx7A-4oavB: 20.90
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4NC3_A_ERMA1202_2 (CHIMERA PROTEIN OF HUMAN 5-HYDROXYTRYPTAMINE RECEPTOR 2B AND E. COLI SOLUBLE CYTOCHROME B562)	4oav	PROTEIN (RNASE L) (Homo sapiens)	4 / 6	THR B 94 LEU B 144 ASN B 119 LEU B 153	None	1.20A	4nc3A-4oavB: undetectable	4nc3A-4oavB: 19.89
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4O0U_A_ADNA501_1 (AURORA KINASE A)	4oav	PROTEIN (RNASE L) (Homo sapiens)	4 / 6	ALA B 390 LYS B 392 THR B 440 LEU B 492	ACP B 801 (-3.2A) ACP B 801 (-2.8A) ACP B 801 (-4.1A) ACP B 801 (-4.5A)	0.78A	4o0uA-4oavB: 17.2	4o0uA-4oavB: 18.68
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4OGR_A_ADNA401_1 (CYCLIN-DEPENDENT KINASE 9)	4oav	PROTEIN (RNASE L) (Homo sapiens)	5 / 8	ILE B 371 ALA B 390 ASN B 490 LEU B 492 ASP B 503	ACP B 801 (-4.2A) ACP B 801 (-3.2A) MG B 802 ( 2.5A) ACP B 801 (-4.5A) MG B 803 (-1.8A)	0.55A	4ogrA-4oavB: 19.1	4ogrA-4oavB: 19.82
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4OGR_E_ADNE401_1 (CYCLIN-DEPENDENT KINASE 9)	4oav	PROTEIN (RNASE L) (Homo sapiens)	5 / 7	ALA B 390 CYH B 437 ASN B 490 LEU B 492 ASP B 503	ACP B 801 (-3.2A) ACP B 801 (-4.5A) MG B 802 ( 2.5A) ACP B 801 (-4.5A) MG B 803 (-1.8A)	0.35A	4ogrE-4oavB: 18.8	4ogrE-4oavB: 19.82
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4OGR_I_ADNI401_1 (CYCLIN-DEPENDENT KINASE 9)	4oav	PROTEIN (RNASE L) (Homo sapiens)	6 / 9	ILE B 371 ALA B 390 CYH B 437 ASN B 490 LEU B 492 ASP B 503	ACP B 801 (-4.2A) ACP B 801 (-3.2A) ACP B 801 (-4.5A) MG B 802 ( 2.5A) ACP B 801 (-4.5A) MG B 803 (-1.8A)	0.58A	4ogrI-4oavB: 19.0	4ogrI-4oavB: 19.82
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4QRC_A_0LIA802_1 (FIBROBLAST GROWTH FACTOR RECEPTOR 4)	4oav	PROTEIN (RNASE L) (Homo sapiens)	5 / 12	ALA B 390 GLU B 404 VAL B 434 LEU B 475 ALA B 502	ACP B 801 (-3.2A) None ACP B 801 (-4.8A) None None	0.99A	4qrcA-4oavB: 17.7	4qrcA-4oavB: 18.13
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4QZU_D_ACTD201_0 (RETINOL-BINDING PROTEIN 2)	4oav	PROTEIN (RNASE L) (Homo sapiens)	3 / 3	ASP B 189 HIS B 228 LYS B 185	None	0.94A	4qzuD-4oavB: undetectable	4qzuD-4oavB: 11.02
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4RZ7_A_1E8A901_1 (CGMP-DEPENDENT PROTEIN KINASE, PUTATIVE)	4oav	PROTEIN (RNASE L) (Homo sapiens)	5 / 10	ILE B 371 ALA B 390 LYS B 392 LEU B 436 LEU B 492	ACP B 801 (-4.2A) ACP B 801 (-3.2A) ACP B 801 (-2.8A) ACP B 801 ( 4.9A) ACP B 801 (-4.5A)	0.72A	4rz7A-4oavB: 16.4	4rz7A-4oavB: 23.11
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4TYJ_A_0LIA801_1 (FIBROBLAST GROWTH FACTOR RECEPTOR 4)	4oav	PROTEIN (RNASE L) (Homo sapiens)	6 / 12	ALA B 390 GLU B 404 VAL B 434 CYH B 479 LEU B 492 ALA B 502	ACP B 801 (-3.2A) None ACP B 801 (-4.8A) None ACP B 801 (-4.5A) None	1.25A	4tyjA-4oavB: 17.7	4tyjA-4oavB: 19.35
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4TYJ_A_0LIA801_1 (FIBROBLAST GROWTH FACTOR RECEPTOR 4)	4oav	PROTEIN (RNASE L) (Homo sapiens)	5 / 12	ALA B 390 VAL B 434 HIS B 483 LEU B 492 ALA B 502	ACP B 801 (-3.2A) ACP B 801 (-4.8A) None ACP B 801 (-4.5A) None	0.65A	4tyjA-4oavB: 17.7	4tyjA-4oavB: 19.35
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4U0I_A_0LIA1001_2 (MAST/STEM CELL GROWTH FACTOR RECEPTOR KIT,MAST/STEM CELL GROWTH FACTOR RECEPTOR KIT)	4oav	PROTEIN (RNASE L) (Homo sapiens)	6 / 12	ALA B 390 LYS B 392 LEU B 408 CYH B 437 HIS B 483 LEU B 492	ACP B 801 (-3.2A) ACP B 801 (-2.8A) None ACP B 801 (-4.5A) None ACP B 801 (-4.5A)	0.59A	4u0iA-4oavB: 17.4	4u0iA-4oavB: 18.44
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4V01_A_0LIA1776_1 (FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B)	4oav	PROTEIN (RNASE L) (Homo sapiens)	5 / 12	ALA B 390 VAL B 434 LEU B 475 HIS B 483 ALA B 502	ACP B 801 (-3.2A) ACP B 801 (-4.8A) None None None	0.82A	4v01A-4oavB: 17.2	4v01A-4oavB: 19.05
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4V01_B_0LIB1770_1 (FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B)	4oav	PROTEIN (RNASE L) (Homo sapiens)	5 / 12	ALA B 390 VAL B 434 LEU B 475 HIS B 483 ALA B 502	ACP B 801 (-3.2A) ACP B 801 (-4.8A) None None None	0.73A	4v01B-4oavB: 17.6	4v01B-4oavB: 19.05
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4V04_B_0LIB1771_2 (FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B)	4oav	PROTEIN (RNASE L) (Homo sapiens)	5 / 12	ALA B 390 VAL B 434 LEU B 475 HIS B 483 ALA B 502	ACP B 801 (-3.2A) ACP B 801 (-4.8A) None None None	0.89A	4v04B-4oavB: 17.7	4v04B-4oavB: 19.05
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4WNW_A_RTZA602_1 (CYTOCHROME P450 2D6)	4oav	PROTEIN (RNASE L) (Homo sapiens)	5 / 12	GLY B 253 LEU B 254 ASP B 227 VAL B 218 VAL B 232	None	1.18A	4wnwA-4oavB: undetectable	4wnwA-4oavB: 21.52
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4XUE_A_SAMA303_0 (CATECHOL O-METHYLTRANSFERASE)	4oav	PROTEIN (RNASE L) (Homo sapiens)	5 / 12	VAL B 389 ILE B 493 ILE B 491 ASN B 490 HIS B 500	None None None MG B 802 ( 2.5A) None	1.09A	4xueA-4oavB: undetectable	4xueA-4oavB: 16.31
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4XV2_B_P06B801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	4oav	PROTEIN (RNASE L) (Homo sapiens)	6 / 12	ALA B 390 LYS B 392 LEU B 408 CYH B 437 ASP B 503 PHE B 504	ACP B 801 (-3.2A) ACP B 801 (-2.8A) None ACP B 801 (-4.5A) MG B 803 (-1.8A) None	0.89A	4xv2B-4oavB: 17.2	4xv2B-4oavB: 18.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5MAF_A_XINA403_2 (MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE)	4oav	PROTEIN (RNASE L) (Homo sapiens)	4 / 5	LEU B 408 CYH B 437 LEU B 492 ASP B 503	None ACP B 801 (-4.5A) ACP B 801 (-4.5A) MG B 803 (-1.8A)	0.86A	5mafA-4oavB: 19.4	5mafA-4oavB: 9.07
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5MO4_A_NILA601_2 (TYROSINE-PROTEIN KINASE ABL1)	4oav	PROTEIN (RNASE L) (Homo sapiens)	6 / 12	ALA B 390 LEU B 417 VAL B 418 HIS B 483 LEU B 492 ALA B 502	ACP B 801 (-3.2A) None None None ACP B 801 (-4.5A) None	0.75A	5mo4A-4oavB: 14.0	5mo4A-4oavB: 21.88
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5ND7_B_TA1B601_1 (TUBULIN BETA-2B CHAIN)	4oav	PROTEIN (RNASE L) (Homo sapiens)	5 / 12	VAL B 33 ASP B 37 GLU B 36 LEU B 63 ALA B 66	None	0.98A	5nd7B-4oavB: undetectable	5nd7B-4oavB: 22.02
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5NM5_B_LOCB502_1 (TUBULIN ALPHA-1B CHAIN TUBULIN BETA-2B CHAIN)	4oav	PROTEIN (RNASE L) (Homo sapiens)	4 / 4	ASN B 414 SER B 467 ALA B 471 VAL B 472	None	1.34A	5nm5A-4oavB: undetectable	5nm5A-4oavB: 23.45
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5OWR_A_1N1A401_1 (SERINE/THREONINE-PRO TEIN KINASE 10)	4oav	PROTEIN (RNASE L) (Homo sapiens)	4 / 8	ALA B 390 CYH B 437 LEU B 492 ASP B 503	ACP B 801 (-3.2A) ACP B 801 (-4.5A) ACP B 801 (-4.5A) MG B 803 (-1.8A)	0.38A	5owrA-4oavB: 17.6	5owrA-4oavB: 18.85
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5VCY_A_DB8A401_2 (MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE)	4oav	PROTEIN (RNASE L) (Homo sapiens)	4 / 4	VAL B 418 LEU B 436 ASN B 490 ASP B 503	None ACP B 801 ( 4.9A) MG B 802 ( 2.5A) MG B 803 (-1.8A)	0.88A	5vcyA-4oavB: 18.4	5vcyA-4oavB: 18.40
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5VKQ_A_PCFA1808_0 (NO MECHANORECEPTOR POTENTIAL C ISOFORM L)	4oav	PROTEIN (RNASE L) (Homo sapiens)	4 / 5	LEU B 285 ALA B 289 LEU B 292 LEU B 316	None	0.82A	5vkqA-4oavB: 15.8 5vkqD-4oavB: 12.6	5vkqA-4oavB: 19.31 5vkqD-4oavB: 19.31
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5VKQ_B_PCFB1805_0 (NO MECHANORECEPTOR POTENTIAL C ISOFORM L)	4oav	PROTEIN (RNASE L) (Homo sapiens)	4 / 5	LEU B 316 LEU B 285 ALA B 289 LEU B 292	None	0.80A	5vkqA-4oavB: 15.8 5vkqB-4oavB: undetectable	5vkqA-4oavB: 19.31 5vkqB-4oavB: 19.31
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5VKQ_C_PCFC1806_0 (NO MECHANORECEPTOR POTENTIAL C ISOFORM L)	4oav	PROTEIN (RNASE L) (Homo sapiens)	4 / 5	LEU B 316 LEU B 285 ALA B 289 LEU B 292	None	0.76A	5vkqB-4oavB: 14.0 5vkqC-4oavB: undetectable	5vkqB-4oavB: 19.31 5vkqC-4oavB: 19.31
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5VKQ_D_PCFD1806_0 (NO MECHANORECEPTOR POTENTIAL C ISOFORM L)	4oav	PROTEIN (RNASE L) (Homo sapiens)	4 / 5	LEU B 316 LEU B 285 ALA B 289 LEU B 292	None	0.83A	5vkqC-4oavB: undetectable 5vkqD-4oavB: 12.6	5vkqC-4oavB: 19.31 5vkqD-4oavB: 19.31
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6AWT_D_BEZD202_0 (PR 10 PROTEIN)	4oav	PROTEIN (RNASE L) (Homo sapiens)	3 / 3	PHE B 665 ASP B 661 LYS B 664	None	0.80A	6awtD-4oavB: undetectable	6awtD-4oavB: 12.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6G9B_A_IXXA609_1 (ENVELOPE GLYCOPROTEIN,ENVELOP E GLYCOPROTEIN ENVELOPE GLYCOPROTEIN)	4oav	PROTEIN (RNASE L) (Homo sapiens)	4 / 7	ILE B 491 LEU B 501 LEU B 486 LEU B 577	None	0.66A	6g9bA-4oavB: undetectable 6g9bB-4oavB: undetectable	6g9bA-4oavB: 7.78 6g9bB-4oavB: 7.58

[["DrReposER ID","Desc.","Hit PDB","Hit molecule","Hit organism","Res. no.","Interface","HETATM","RMSD","Z-score","Seq ID"],["1DMA_B_NCAB700_0","EXOTOXIN A","4oav","PROTEIN (RNASE L)","Homo sapiens",4,"HIS B 180;TYR B 135;ALA B 133;GLU B 131","None;None;None;  A C   3 ( 2.7A)","1.01A","1dmaB-4oavB:undetectable","1dmaB-4oavB:14.86"],["1EQG_A_IBPA701_1","PROSTAGLANDIN H2 SYNTHASE-1","4oav","PROTEIN (RNASE L)","Homo sapiens",5,"VAL B 418;VAL B 432;LEU B 408;ILE B 379;ALA B 390","None;None;None;ACP B 801 (-4.0A);ACP B 801 (-3.2A)","1.09A","1eqgA-4oavB:undetectable","1eqgA-4oavB:22.55"],["1EQG_B_IBPB1701_1","PROSTAGLANDIN H2 SYNTHASE-1","4oav","PROTEIN (RNASE L)","Homo sapiens",5,"VAL B 418;VAL B 432;LEU B 408;ILE B 379;ALA B 390","None;None;None;ACP B 801 (-4.0A);ACP B 801 (-3.2A)","1.08A","1eqgB-4oavB:undetectable","1eqgB-4oavB:22.55"],["1MRQ_A_STRA501_1","ALDO-KETO REDUCTASE FAMILY 1 MEMBER C1","4oav","PROTEIN (RNASE L)","Homo sapiens",5,"LEU B 707;GLU B 613;ILE B 614;LEU B 596;LEU B 663","None","1.35A","1mrqA-4oavB:undetectable","1mrqA-4oavB:19.51"],["1RS6_B_MTLB871_0","NITRIC-OXIDE SYNTHASE, BRAIN","4oav","PROTEIN (RNASE L)","Homo sapiens",4,"ARG B 597;GLN B 693;PHE B 692;ASP B 687","None","1.31A","1rs6B-4oavB:undetectable","1rs6B-4oavB:20.79"],["1UWH_A_BAXA1723_1","B-RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","4oav","PROTEIN (RNASE L)","Homo sapiens",5,"ALA B 390;LEU B 408;CYH B 437;LEU B 475;HIS B 483","ACP B 801 (-3.2A);None;ACP B 801 (-4.5A);None;None","0.66A","1uwhA-4oavB:17.1","1uwhA-4oavB:18.00"],["1UWH_B_BAXB1723_1","B-RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","4oav","PROTEIN (RNASE L)","Homo sapiens",6,"ALA B 390;LYS B 392;LEU B 408;CYH B 437;LEU B 475;HIS B 483","ACP B 801 (-3.2A);ACP B 801 (-2.8A);None;ACP B 801 (-4.5A);None;None","0.79A","1uwhB-4oavB:17.1","1uwhB-4oavB:18.00"],["1XZX_X_T3X500_2","THYROID HORMONE RECEPTOR BETA-1","4oav","PROTEIN (RNASE L)","Homo sapiens",3,"PHE B 716;ARG B 597;ASN B 598","None","0.85A","1xzxX-4oavB:undetectable","1xzxX-4oavB:16.14"],["1ZZQ_A_MTLA870_0","NITRIC-OXIDE SYNTHASE, BRAIN","4oav","PROTEIN (RNASE L)","Homo sapiens",4,"ARG B 597;GLN B 693;PHE B 692;ASP B 687","None","1.29A","1zzqA-4oavB:undetectable","1zzqA-4oavB:20.06"],["1ZZQ_B_MTLB871_0","NITRIC-OXIDE SYNTHASE, BRAIN","4oav","PROTEIN (RNASE L)","Homo sapiens",4,"ARG B 597;GLN B 693;PHE B 692;ASP B 687","None","1.27A","1zzqB-4oavB:undetectable","1zzqB-4oavB:20.06"],["2BXQ_A_IMNA2001_1","SERUM ALBUMIN","4oav","PROTEIN (RNASE L)","Homo sapiens",5,"ALA B 128;PHE B 129;ALA B 133;LEU B 187;LEU B 108","None","1.06A","2bxqA-4oavB:2.6","2bxqA-4oavB:22.53"],["2C49_B_ADNB1301_1","SUGAR KINASE MJ0406","4oav","PROTEIN (RNASE L)","Homo sapiens",5,"ALA B 169;GLY B 168;GLY B 167;ASN B 200;PHE B 126","  A C   3 ( 4.6A);None;  A C   3 ( 4.4A);None;  A C   3 ( 3.6A)","1.16A","2c49B-4oavB:undetectable","2c49B-4oavB:18.30"],["2EUF_B_LQQB401_1","CELL DIVISION PROTEIN KINASE 6","4oav","PROTEIN (RNASE L)","Homo sapiens",7,"ILE B 371;LYS B 392;VAL B 418;ASN B 490;LEU B 492;ALA B 502;ASP B 503","ACP B 801 (-4.2A);ACP B 801 (-2.8A);None; MG B 802 ( 2.5A);ACP B 801 (-4.5A);None; MG B 803 (-1.8A)","0.81A","2eufB-4oavB:19.6","2eufB-4oavB:18.53"],["2PNJ_A_CHDA501_0","FERROCHELATASE, MITOCHONDRIAL","4oav","PROTEIN (RNASE L)","Homo sapiens",5,"LEU B 527;LEU B 524;LEU B 521;ILE B 491;LEU B 477","None","1.09A","2pnjA-4oavB:undetectable","2pnjA-4oavB:19.80"],["2Y7H_B_SAMB530_0","TYPE I RESTRICTION ENZYME ECOKI M PROTEIN","4oav","PROTEIN (RNASE L)","Homo sapiens",5,"ILE B 371;ALA B 502;THR B 440;LEU B 475;PHE B 504","ACP B 801 (-4.2A);None;ACP B 801 (-4.1A);None;None","1.08A","2y7hB-4oavB:undetectable","2y7hB-4oavB:21.92"],["2Y7H_C_SAMC530_0","TYPE I RESTRICTION ENZYME ECOKI M PROTEIN","4oav","PROTEIN (RNASE L)","Homo sapiens",5,"ILE B 371;ALA B 502;THR B 440;LEU B 475;PHE B 504","ACP B 801 (-4.2A);None;ACP B 801 (-4.1A);None;None","1.07A","2y7hC-4oavB:undetectable","2y7hC-4oavB:21.92"],["3IK3_A_0LIA1_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","4oav","PROTEIN (RNASE L)","Homo sapiens",6,"ALA B 390;LEU B 417;VAL B 418;HIS B 483;LEU B 492;ALA B 502","ACP B 801 (-3.2A);None;None;None;ACP B 801 (-4.5A);None","0.74A","3ik3A-4oavB:16.8","3ik3A-4oavB:17.11"],["3IK3_B_0LIB2_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","4oav","PROTEIN (RNASE L)","Homo sapiens",5,"ALA B 390;LEU B 417;HIS B 483;LEU B 492;ALA B 502","ACP B 801 (-3.2A);None;None;ACP B 801 (-4.5A);None","0.57A","3ik3B-4oavB:16.6","3ik3B-4oavB:17.11"],["3IK3_B_0LIB2_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","4oav","PROTEIN (RNASE L)","Homo sapiens",5,"LEU B 417;VAL B 418;HIS B 483;LEU B 492;ALA B 502","None;None;None;ACP B 801 (-4.5A);None","0.70A","3ik3B-4oavB:16.6","3ik3B-4oavB:17.11"],["3WIP_G_ACTG305_0","ACETYLCHOLINE-BINDING PROTEIN","4oav","PROTEIN (RNASE L)","Homo sapiens",3,"ASP B 485;ARG B 400;LYS B 506"," MG B 803 (-4.7A);ACP B 801 (-3.1A);ACP B 801 ( 4.8A)","0.95A","3wipG-4oavB:undetectable","3wipG-4oavB:15.87"],["4AGD_A_B49A2000_1","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","4oav","PROTEIN (RNASE L)","Homo sapiens",5,"ALA B 390;VAL B 418;VAL B 434;CYH B 437;LEU B 492","ACP B 801 (-3.2A);None;ACP B 801 (-4.8A);ACP B 801 (-4.5A);ACP B 801 (-4.5A)","0.55A","4agdA-4oavB:17.0","4agdA-4oavB:19.86"],["4DX7_A_DM2A1105_1","ACRIFLAVINE RESISTANCE PROTEIN B","4oav","PROTEIN (RNASE L)","Homo sapiens",5,"MET B 130;PHE B 126;GLY B 202;ARG B 154;GLU B 162","None;  A C   3 ( 3.6A);None;None;None","1.48A","4dx7A-4oavB:0.1","4dx7A-4oavB:20.90"],["4NC3_A_ERMA1202_2","CHIMERA PROTEIN OF HUMAN 5-HYDROXYTRYPTAMINE RECEPTOR 2B AND E. COLI SOLUBLE CYTOCHROME B562","4oav","PROTEIN (RNASE L)","Homo sapiens",4,"THR B  94;LEU B 144;ASN B 119;LEU B 153","None","1.20A","4nc3A-4oavB:undetectable","4nc3A-4oavB:19.89"],["4O0U_A_ADNA501_1","AURORA KINASE A","4oav","PROTEIN (RNASE L)","Homo sapiens",4,"ALA B 390;LYS B 392;THR B 440;LEU B 492","ACP B 801 (-3.2A);ACP B 801 (-2.8A);ACP B 801 (-4.1A);ACP B 801 (-4.5A)","0.78A","4o0uA-4oavB:17.2","4o0uA-4oavB:18.68"],["4OGR_A_ADNA401_1","CYCLIN-DEPENDENT KINASE 9","4oav","PROTEIN (RNASE L)","Homo sapiens",5,"ILE B 371;ALA B 390;ASN B 490;LEU B 492;ASP B 503","ACP B 801 (-4.2A);ACP B 801 (-3.2A); MG B 802 ( 2.5A);ACP B 801 (-4.5A); MG B 803 (-1.8A)","0.55A","4ogrA-4oavB:19.1","4ogrA-4oavB:19.82"],["4OGR_E_ADNE401_1","CYCLIN-DEPENDENT KINASE 9","4oav","PROTEIN (RNASE L)","Homo sapiens",5,"ALA B 390;CYH B 437;ASN B 490;LEU B 492;ASP B 503","ACP B 801 (-3.2A);ACP B 801 (-4.5A); MG B 802 ( 2.5A);ACP B 801 (-4.5A); MG B 803 (-1.8A)","0.35A","4ogrE-4oavB:18.8","4ogrE-4oavB:19.82"],["4OGR_I_ADNI401_1","CYCLIN-DEPENDENT KINASE 9","4oav","PROTEIN (RNASE L)","Homo sapiens",6,"ILE B 371;ALA B 390;CYH B 437;ASN B 490;LEU B 492;ASP B 503","ACP B 801 (-4.2A);ACP B 801 (-3.2A);ACP B 801 (-4.5A); MG B 802 ( 2.5A);ACP B 801 (-4.5A); MG B 803 (-1.8A)","0.58A","4ogrI-4oavB:19.0","4ogrI-4oavB:19.82"],["4QRC_A_0LIA802_1","FIBROBLAST GROWTH FACTOR RECEPTOR 4","4oav","PROTEIN (RNASE L)","Homo sapiens",5,"ALA B 390;GLU B 404;VAL B 434;LEU B 475;ALA B 502","ACP B 801 (-3.2A);None;ACP B 801 (-4.8A);None;None","0.99A","4qrcA-4oavB:17.7","4qrcA-4oavB:18.13"],["4QZU_D_ACTD201_0","RETINOL-BINDING PROTEIN 2","4oav","PROTEIN (RNASE L)","Homo sapiens",3,"ASP B 189;HIS B 228;LYS B 185","None","0.94A","4qzuD-4oavB:undetectable","4qzuD-4oavB:11.02"],["4RZ7_A_1E8A901_1","CGMP-DEPENDENT PROTEIN KINASE, PUTATIVE","4oav","PROTEIN (RNASE L)","Homo sapiens",5,"ILE B 371;ALA B 390;LYS B 392;LEU B 436;LEU B 492","ACP B 801 (-4.2A);ACP B 801 (-3.2A);ACP B 801 (-2.8A);ACP B 801 ( 4.9A);ACP B 801 (-4.5A)","0.72A","4rz7A-4oavB:16.4","4rz7A-4oavB:23.11"],["4TYJ_A_0LIA801_1","FIBROBLAST GROWTH FACTOR RECEPTOR 4","4oav","PROTEIN (RNASE L)","Homo sapiens",6,"ALA B 390;GLU B 404;VAL B 434;CYH B 479;LEU B 492;ALA B 502","ACP B 801 (-3.2A);None;ACP B 801 (-4.8A);None;ACP B 801 (-4.5A);None","1.25A","4tyjA-4oavB:17.7","4tyjA-4oavB:19.35"],["4TYJ_A_0LIA801_1","FIBROBLAST GROWTH FACTOR RECEPTOR 4","4oav","PROTEIN (RNASE L)","Homo sapiens",5,"ALA B 390;VAL B 434;HIS B 483;LEU B 492;ALA B 502","ACP B 801 (-3.2A);ACP B 801 (-4.8A);None;ACP B 801 (-4.5A);None","0.65A","4tyjA-4oavB:17.7","4tyjA-4oavB:19.35"],["4U0I_A_0LIA1001_2","MAST\/STEM CELL GROWTH FACTOR RECEPTOR KIT,MAST\/STEM CELL GROWTH FACTOR RECEPTOR KIT","4oav","PROTEIN (RNASE L)","Homo sapiens",6,"ALA B 390;LYS B 392;LEU B 408;CYH B 437;HIS B 483;LEU B 492","ACP B 801 (-3.2A);ACP B 801 (-2.8A);None;ACP B 801 (-4.5A);None;ACP B 801 (-4.5A)","0.59A","4u0iA-4oavB:17.4","4u0iA-4oavB:18.44"],["4V01_A_0LIA1776_1","FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B","4oav","PROTEIN (RNASE L)","Homo sapiens",5,"ALA B 390;VAL B 434;LEU B 475;HIS B 483;ALA B 502","ACP B 801 (-3.2A);ACP B 801 (-4.8A);None;None;None","0.82A","4v01A-4oavB:17.2","4v01A-4oavB:19.05"],["4V01_B_0LIB1770_1","FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B","4oav","PROTEIN (RNASE L)","Homo sapiens",5,"ALA B 390;VAL B 434;LEU B 475;HIS B 483;ALA B 502","ACP B 801 (-3.2A);ACP B 801 (-4.8A);None;None;None","0.73A","4v01B-4oavB:17.6","4v01B-4oavB:19.05"],["4V04_B_0LIB1771_2","FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B","4oav","PROTEIN (RNASE L)","Homo sapiens",5,"ALA B 390;VAL B 434;LEU B 475;HIS B 483;ALA B 502","ACP B 801 (-3.2A);ACP B 801 (-4.8A);None;None;None","0.89A","4v04B-4oavB:17.7","4v04B-4oavB:19.05"],["4WNW_A_RTZA602_1","CYTOCHROME P450 2D6","4oav","PROTEIN (RNASE L)","Homo sapiens",5,"GLY B 253;LEU B 254;ASP B 227;VAL B 218;VAL B 232","None","1.18A","4wnwA-4oavB:undetectable","4wnwA-4oavB:21.52"],["4XUE_A_SAMA303_0","CATECHOL O-METHYLTRANSFERASE","4oav","PROTEIN (RNASE L)","Homo sapiens",5,"VAL B 389;ILE B 493;ILE B 491;ASN B 490;HIS B 500","None;None;None; MG B 802 ( 2.5A);None","1.09A","4xueA-4oavB:undetectable","4xueA-4oavB:16.31"],["4XV2_B_P06B801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","4oav","PROTEIN (RNASE L)","Homo sapiens",6,"ALA B 390;LYS B 392;LEU B 408;CYH B 437;ASP B 503;PHE B 504","ACP B 801 (-3.2A);ACP B 801 (-2.8A);None;ACP B 801 (-4.5A); MG B 803 (-1.8A);None","0.89A","4xv2B-4oavB:17.2","4xv2B-4oavB:18.53"],["5MAF_A_XINA403_2","MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE","4oav","PROTEIN (RNASE L)","Homo sapiens",4,"LEU B 408;CYH B 437;LEU B 492;ASP B 503","None;ACP B 801 (-4.5A);ACP B 801 (-4.5A); MG B 803 (-1.8A)","0.86A","5mafA-4oavB:19.4","5mafA-4oavB:9.07"],["5MO4_A_NILA601_2","TYROSINE-PROTEIN KINASE ABL1","4oav","PROTEIN (RNASE L)","Homo sapiens",6,"ALA B 390;LEU B 417;VAL B 418;HIS B 483;LEU B 492;ALA B 502","ACP B 801 (-3.2A);None;None;None;ACP B 801 (-4.5A);None","0.75A","5mo4A-4oavB:14.0","5mo4A-4oavB:21.88"],["5ND7_B_TA1B601_1","TUBULIN BETA-2B CHAIN","4oav","PROTEIN (RNASE L)","Homo sapiens",5,"VAL B  33;ASP B  37;GLU B  36;LEU B  63;ALA B  66","None","0.98A","5nd7B-4oavB:undetectable","5nd7B-4oavB:22.02"],["5NM5_B_LOCB502_1","TUBULIN ALPHA-1B CHAIN;TUBULIN BETA-2B CHAIN","4oav","PROTEIN (RNASE L)","Homo sapiens",4,"ASN B 414;SER B 467;ALA B 471;VAL B 472","None","1.34A","5nm5A-4oavB:undetectable","5nm5A-4oavB:23.45"],["5OWR_A_1N1A401_1","SERINE\/THREONINE-PROTEIN KINASE 10","4oav","PROTEIN (RNASE L)","Homo sapiens",4,"ALA B 390;CYH B 437;LEU B 492;ASP B 503","ACP B 801 (-3.2A);ACP B 801 (-4.5A);ACP B 801 (-4.5A); MG B 803 (-1.8A)","0.38A","5owrA-4oavB:17.6","5owrA-4oavB:18.85"],["5VCY_A_DB8A401_2","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","4oav","PROTEIN (RNASE L)","Homo sapiens",4,"VAL B 418;LEU B 436;ASN B 490;ASP B 503","None;ACP B 801 ( 4.9A); MG B 802 ( 2.5A); MG B 803 (-1.8A)","0.88A","5vcyA-4oavB:18.4","5vcyA-4oavB:18.40"],["5VKQ_A_PCFA1808_0","NO MECHANORECEPTOR POTENTIAL C ISOFORM L","4oav","PROTEIN (RNASE L)","Homo sapiens",4,"LEU B 285;ALA B 289;LEU B 292;LEU B 316","None","0.82A","5vkqA-4oavB:15.8;5vkqD-4oavB:12.6","5vkqA-4oavB:19.31;5vkqD-4oavB:19.31"],["5VKQ_B_PCFB1805_0","NO MECHANORECEPTOR POTENTIAL C ISOFORM L","4oav","PROTEIN (RNASE L)","Homo sapiens",4,"LEU B 316;LEU B 285;ALA B 289;LEU B 292","None","0.80A","5vkqA-4oavB:15.8;5vkqB-4oavB:undetectable","5vkqA-4oavB:19.31;5vkqB-4oavB:19.31"],["5VKQ_C_PCFC1806_0","NO MECHANORECEPTOR POTENTIAL C ISOFORM L","4oav","PROTEIN (RNASE L)","Homo sapiens",4,"LEU B 316;LEU B 285;ALA B 289;LEU B 292","None","0.76A","5vkqB-4oavB:14.0;5vkqC-4oavB:undetectable","5vkqB-4oavB:19.31;5vkqC-4oavB:19.31"],["5VKQ_D_PCFD1806_0","NO MECHANORECEPTOR POTENTIAL C ISOFORM L","4oav","PROTEIN (RNASE L)","Homo sapiens",4,"LEU B 316;LEU B 285;ALA B 289;LEU B 292","None","0.83A","5vkqC-4oavB:undetectable;5vkqD-4oavB:12.6","5vkqC-4oavB:19.31;5vkqD-4oavB:19.31"],["6AWT_D_BEZD202_0","PR 10 PROTEIN","4oav","PROTEIN (RNASE L)","Homo sapiens",3,"PHE B 665;ASP B 661;LYS B 664","None","0.80A","6awtD-4oavB:undetectable","6awtD-4oavB:12.22"],["6G9B_A_IXXA609_1","ENVELOPE GLYCOPROTEIN,ENVELOPE GLYCOPROTEIN;ENVELOPE GLYCOPROTEIN","4oav","PROTEIN (RNASE L)","Homo sapiens",4,"ILE B 491;LEU B 501;LEU B 486;LEU B 577","None","0.66A","6g9bA-4oavB:undetectable;6g9bB-4oavB:undetectable","6g9bA-4oavB:7.78;6g9bB-4oavB:7.58"]]